AOD-9604

Mechanism of Action

AOD-9604 is a synthetic peptide corresponding to the C-terminal fragment (amino acids 177-191) of human growth hormone with an added tyrosine residue at the N-terminus. It was designed to retain the fat-burning properties of hGH while eliminating its effects on growth, insulin resistance, and other metabolic parameters.

Research suggests AOD-9604 stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat formation) through mechanisms that are independent of the growth hormone receptor. Instead, it appears to act through the stimulation of beta-3 adrenergic receptors and modulation of metabolic pathways in adipose tissue.

Importantly, AOD-9604 does not appear to affect blood glucose levels or insulin sensitivity, distinguishing it from full growth hormone and other GH secretagogues.

Reported Effects

Commonly Reported

• Increased fat oxidation in obese rodent models
• Reduction in body fat without changes to lean mass
• No adverse effects on blood glucose or insulin sensitivity
• Accelerated cartilage repair in animal models

Less Common Reports

• Improved lipid profiles
• Anti-inflammatory properties in cartilage tissue
• Potential bone regenerative effects
• Enhanced metabolic rate in some animal studies

Phase II data available from trials conducted by Metabolic Pharmaceuticals.

Side Effects & Safety Profile

Low Concern

• Mild injection site reactions
• Headache (occasional)
• Generally well-tolerated in clinical trials

Moderate Concern

• Limited long-term human safety data
• Efficacy at oral doses is variable
• Potential for tolerance with extended use

Serious

• No serious adverse events reported in clinical trials
• Does not appear to affect IGF-1 levels (reducing GH-related risks)
• Well-tolerated in Phase II human trials

Clinical Evidence

• Phase II obesity trial — Metabolic Pharmaceuticals conducted trials showing dose-dependent fat loss in obese subjects
• Pre-clinical lipolysis — Multiple rodent studies demonstrating selective fat mobilization
• Cartilage repair — Animal models showing accelerated cartilage healing in joint injury paradigms
• Safety profile — Phase II trials demonstrated acceptable safety with no impact on glucose metabolism

FDA orphan drug designation for cartilage repair was sought but not granted.

Discovery Timeline

• 1990s — hGH fragment 177-191 identified as a lipolytic agent
• 2000 — AOD-9604 (modified fragment) developed by Metabolic Pharmaceuticals
• 2003–2006 — Phase II trials for obesity
• 2007 — Metabolic Pharmaceuticals ceases operations; development halted
• 2010s — Research interest renewed for fat metabolism and cartilage applications
• 2020s — Ongoing pre-clinical research in cartilage and metabolic health

Community Research Notes

The following testimonials are drawn from r/Peptides and r/Biohackers. Individual experiences vary. Nothing here constitutes medical advice.

"I had been stuck at the same body fat percentage for months despite clean eating and regular training. After 8 weeks on AOD-9604, the lower belly area finally started to lean out." — r/Peptides user

"The most boring peptide I have ever used, but it works. The fat loss was slow but consistent, and it specifically targeted areas that had been resistant to diet and exercise alone." — r/Biohackers user

"I documented a protocol of 1 mg per session, 2 to 3 times per week, subcutaneously into the fat under the chin, over 6 to 8 weeks. Visible improvement in submental fat." — r/Peptides user

Frequently Asked Questions

Is AOD-9604 safe? The safety data is among the strongest of any peptide. Over 900 participants across six human clinical trials showed adverse event rates comparable to placebo. No serious side effects were reported.

Does AOD-9604 actually work for fat loss? The preclinical data is convincing, and anecdotal reports support fat loss, particularly in stubborn areas. The largest clinical trial did not reach statistical significance on its primary endpoint, which is why it was not developed as a pharmaceutical. Results appear to be moderate rather than dramatic.

How long before I see results? Most research protocols run 8 to 16 weeks. Users typically notice changes in stubborn fat areas around weeks 6 to 8. Clinical trials lasted up to 24 weeks.

Can AOD-9604 be used for spot reduction? Some research communities use localized injections for specific fat deposits. The evidence for this is primarily anecdotal. The systemic fat loss effect is better supported by data.

What is the difference between AOD-9604 and HGH? AOD-9604 is a 15-amino-acid fragment of HGH designed to carry only the fat-burning properties. Full HGH affects muscle growth, organ growth, IGF-1 levels, and insulin sensitivity. AOD-9604 does none of these things.

Compounds That Pair Well

• 5-Amino-1MQ — Dual-mechanism fat loss. AOD-9604 mobilizes fat through beta-3 adrenergic receptors; 5-Amino-1MQ increases metabolic rate through a distinct pathway, producing complementary effects.
• CJC-1295 / Ipamorelin — Body recomposition stack. GH release from these peptides supports lean mass preservation while AOD-9604 handles fat mobilization.
• Tesamorelin — Visceral fat reduction through a complementary GH-mediated mechanism, amplifying AOD-9604's abdominal fat effects.
• MOTS-c — Enhanced exercise capacity and metabolic efficiency alongside fat burning.
• Retatrutide — Appetite suppression and caloric deficit management while AOD-9604 accelerates fat mobilization.

Build Your Personalised Protocol

AOD-9604 is one of many compounds available in the BioStack Generator. Explore fat metabolism stacks alongside other peptide compounds.

Get Your BioStack →